Hormone Replacement Therapy and Heart Risk: What the Evidence Actually Says

You're in your early fifties. The hot flashes have started waking you at 3 AM, sleep is a wreck, your mood has gotten short with people you love, and your gynecologist has brought up hormone therapy. You looked it up online and the first three results say it causes heart attacks. The fourth says it prevents them. Your sister tells you her best friend's mother had a stroke on the patch. You come into my clinic because your gynecologist wants a cardiology read before starting anything, and you're not sure what to believe.

I see this conversation in my office almost every week. Hormone replacement therapy, or HRT, is one of the most misunderstood topics in women's heart health. The headlines from twenty years ago scared a generation of women off it. The pendulum has swung back, and the modern picture is more nuanced than either the old "estrogen prevents heart attacks" optimism or the post-2002 "estrogen kills" panic. The truth is that timing matters, the route the hormone takes matters, your personal risk profile matters, and the difference between estrogen alone and estrogen plus a progestin matters. None of those distinctions made it into the original news cycle.

This article walks through what the evidence says about HRT and the heart in 2026, who tends to benefit, who shouldn't go near it, and how I think about counseling patients in clinic. If you've been told flatly that HRT causes heart attacks, or flatly that it prevents them, you've been told something incomplete.

Why Menopause Changes the Heart

For most of a woman's reproductive life, her heart and blood vessels are protected by estrogen in ways we still don't fully understand. Estrogen helps keep the inside lining of arteries flexible and responsive, keeps cholesterol numbers more favorable, and seems to dampen the kind of inflammation that drives plaque buildup. Women in their thirties and forties have heart attacks at roughly a third the rate of men the same age. That gap closes as menopause arrives.

When the ovaries stop producing estrogen, several things shift. LDL cholesterol tends to climb. HDL drops. Blood pressure often creeps up. Visceral fat increases. Insulin resistance gets a little worse. The lining of the arteries becomes stiffer and less responsive. Within five to ten years of the last menstrual period, the rate of heart attacks in women starts catching up to men, and by the seventies the rates are about equal. Most of my female patients with new coronary disease are postmenopausal.

That biology is the reason researchers spent decades wondering whether replacing estrogen after menopause might protect the heart. Observational studies in the 1980s and 1990s suggested it did. Women on HRT had fewer heart attacks than women not on it. The medical community was so confident that estrogen was cardioprotective that for a while it was being prescribed almost as a preventive measure. Then a large randomized trial blew that up.

The Big Surprise (And What It Didn't Tell Us)

In the early 2000s, a major US trial enrolled more than 16,000 postmenopausal women and randomly assigned them to take either oral estrogen plus a synthetic progestin or a placebo. The trial was stopped early because the women on the hormones had more breast cancers, more strokes, and more blood clots than the placebo group. Heart attacks were not reduced. Coverage was everywhere. Prescriptions for HRT dropped by more than half within a year. A whole generation of women either stopped their hormones cold or never started.

Here's what the headlines didn't say. The average woman in that trial was 63 years old at the start. Many of them were more than ten years past their last period. Many had high blood pressure, were overweight, or had other cardiovascular risk factors already baked in. They were taking an oral form of estrogen and a particular synthetic progestin that we now know behaves differently from progesterone made in your own body. The trial was not designed around women in their early fifties starting hormones for hot flashes. It was designed around older women, started years after menopause, on a specific oral combination.

When researchers went back and looked at the women in that same trial who were closer to menopause when they started, the picture changed. Women who started hormones within ten years of their last period had numerically fewer heart events than women who started later. The increased risk that drove the headlines was concentrated in the older subgroup. That observation became the basis for what cardiologists and gynecologists now call the timing hypothesis.

The Timing Hypothesis

The idea is straightforward. Estrogen seems to be good for arteries that are still healthy. It seems to be neutral or somewhat harmful for arteries that already have plaque sitting in them. The reason makes biological sense. Healthy artery walls respond to estrogen by staying flexible and resisting plaque formation. Arteries with established plaque can have that plaque destabilized when estrogen exposure changes, raising the chance of a clot or rupture.

If you start HRT in your early fifties, within a few years of your last period, your arteries are likely still in the "healthy" category, and the biological picture favors benefit or at least neutrality. If you start HRT in your sixties or seventies, after a decade or more of postmenopausal arterial change, the same hormone may push silent plaque in the wrong direction.

Two trials in the 2010s tested this idea directly. One looked at younger postmenopausal women, mostly within six years of menopause, and used coronary calcium scoring and ultrasound measurements of artery wall thickness to track what was happening in their arteries. Women on oral estrogen had less progression of artery wall thickening than women on placebo. A separate trial randomly assigned women to oral hormone therapy starting either within six years of menopause or more than ten years out. The early-start group had measurable slowing of artery wall thickening. The late-start group did not. Neither trial was large enough to count heart attacks, and the imaging data lined up with what the timing hypothesis predicted.

Where this leaves us in clinic: if you're a healthy woman in your early fifties with bothersome symptoms and no contraindications, HRT is unlikely to raise your cardiac risk in any meaningful way and may carry a small benefit. If you're 65 with no symptoms and you're asking about HRT for heart protection, the answer is no. We don't start HRT for prevention. We start it for symptoms, and we factor in your cardiac picture as part of the safety check.

Pill Versus Patch: Why the Route Matters for Clot Risk

One of the biggest changes in modern HRT prescribing is the move away from oral estrogen toward transdermal estrogen for most patients. The pill and the patch behave differently in your body in ways that matter for the heart and for clot risk.

When you swallow estrogen, it goes through your stomach and intestines, then straight to your liver before it ever reaches the rest of your body. The way your liver breaks down that first dose of estrogen ramps up production of certain clotting proteins. The result is a measurable rise in your tendency to form clots in deep veins and a small rise in stroke risk. The risk is real and it shows up in the trial data, most clearly with the older synthetic oral preparations.

A patch or a gel delivers estrogen through the skin and into the bloodstream, skipping the liver pass entirely. The clotting protein bump doesn't happen. Multiple large observational studies have found that women on transdermal estrogen have rates of deep vein clots and stroke that look about the same as women not on hormones at all. The original trial that scared everyone used oral estrogen. We now have decades of data suggesting the patch tells a different story.

In my clinic, when a patient is starting HRT and has any cardiovascular risk factors at all (high blood pressure, family history of clots, migraine with aura, obesity, smoking history), I push hard for the patch over the pill. For a healthy woman with none of those flags, the difference is smaller, and I still tend to recommend transdermal because the safety margin is wider. The Menopause Society's 2022 position statement explicitly favors transdermal for women with elevated baseline clot risk, and many gynecologists now reach for it as a first line.

Estrogen Alone Versus Estrogen Plus a Progestin

If you still have your uterus, you can't take estrogen by itself. Unopposed estrogen makes the lining of the uterus grow, and over time that growth can become endometrial cancer. To prevent that, women with a uterus take a progestin alongside the estrogen, which keeps the lining in check.

Women who've had a hysterectomy don't need the progestin. They take estrogen alone, and the data on estrogen-only HRT look more favorable than the data on combined therapy. In the same major trial that flagged risks with estrogen plus progestin, the estrogen-only arm in women who'd had hysterectomies didn't show the same increase in breast cancer or heart attacks. Stroke and clot risk with oral estrogen were still elevated. The combined hormone story and the estrogen-only story aren't the same.

For women who do need a progestin, the type matters too. The synthetic progestin used in the original trial (medroxyprogesterone acetate) has fallen out of favor for several reasons, including some evidence that it partially blunts estrogen's effects on the artery wall. Most prescribers now use micronized progesterone, which is structurally identical to the progesterone your own body made before menopause. Observational data suggest micronized progesterone is more neutral on breast cancer and clot risk than the older synthetics. Long-term randomized trial data on micronized progesterone aren't as deep as we'd like, and the trend has been to use it preferentially when a progestin is required.

Who's a Good Candidate for HRT From a Heart Perspective

Here's how I think through it in clinic. A woman who's a reasonable candidate for HRT from a cardiac standpoint usually has most of the following:

She's within ten years of her last menstrual period, ideally within five or six. Her symptoms are bothering her enough to affect sleep, work, mood, or relationships. Her blood pressure is controlled. She doesn't have known coronary disease, prior heart attack, or prior stroke. She doesn't have a personal history of breast cancer or a known high-risk genetic mutation for breast cancer. She doesn't have a personal history of deep vein clots or pulmonary embolism. She doesn't have active liver disease. She isn't a current smoker, or if she's smoking, she's working on quitting.

For that woman, the cardiovascular conversation about HRT is mostly reassurance. The risk of starting transdermal estrogen with micronized progesterone (or estrogen alone if she's had a hysterectomy) is small. The benefit on quality of life can be transformative. I don't pretend HRT is a heart medication. I tell her it's a quality-of-life medication with a reasonable cardiac risk profile in her situation.

A woman with one or two risk factors (mild hypertension, a sister with breast cancer, modestly elevated LDL) isn't disqualified. We have the conversation, we use transdermal where possible, we keep the dose at the lowest effective level, and we recheck every year.

Who Shouldn't Take HRT

There are situations where I'd advise against starting systemic HRT, or recommend stopping it if it's been started.

A woman with active coronary artery disease, an unstable angina pattern, or a recent heart attack should not be on systemic estrogen. The risk of triggering a cardiac event in the setting of established disease is real. If she's already on HRT when she has a cardiac event, we typically taper her off in coordination with her gynecologist.

A woman with a prior stroke or transient ischemic attack should not be on systemic estrogen. The data on stroke recurrence with HRT in this group is unfavorable.

A woman with a personal history of breast cancer, especially hormone-receptor-positive disease, should not be on systemic HRT. The breast cancer concern outweighs the menopausal symptom benefit, and there are non-hormonal options for hot flashes that work well enough for most women in this group.

A woman with a personal history of deep vein clots, pulmonary embolism, or a known clotting disorder should not be on oral estrogen. Transdermal estrogen has been used cautiously in some of these patients in close consultation with hematology, and most prescribers steer clear unless there's a strong indication and a careful risk discussion.

A woman with active liver disease, undiagnosed vaginal bleeding, or pregnancy should not start HRT until those issues are sorted out.

A woman well past 65 with no symptoms who's asking about HRT for prevention should not start it. We have better tools for cardiovascular prevention in that age group, and the risk-benefit calculation for a fresh start of HRT past that age tilts toward harm.

Vaginal Estrogen and the Heart

Many of the women I see in clinic are not asking about systemic HRT. They're asking about vaginal symptoms: dryness, painful sex, recurrent urinary tract infections. These are real, common, and often go untreated for years because patients are too embarrassed to bring them up and clinicians are too rushed to ask.

Low-dose vaginal estrogen (a cream, a tablet, or a ring) is a different drug from systemic HRT, despite using the same molecule. The dose is so low and the absorption into the rest of the body is so minimal that blood estrogen levels barely move. Vaginal estrogen has not been shown to raise the risk of heart attack, stroke, blood clots, or breast cancer recurrence in any meaningful way. The Menopause Society and most breast cancer organizations now consider it acceptable for many women with a history of breast cancer, in coordination with their oncologist.

If your only menopausal symptoms are vaginal or urinary, vaginal estrogen is the right answer for most patients, and it carries none of the cardiovascular concern that comes with the systemic forms. I bring this up because patients sometimes refuse vaginal estrogen out of fear that came from the systemic HRT headlines twenty years ago. The two drugs aren't comparable in cardiovascular impact.

How Long to Stay on HRT

There's no fixed expiration date on HRT, and the old rule of "five years and you're out" has softened a lot. The current view from the Menopause Society and most gynecologic groups is that HRT can continue as long as the symptoms it's treating are present and the woman is being followed by a clinician who's reviewing her risk profile each year.

In practice, I see most of my patients on HRT for somewhere between two and seven years. Hot flashes resolve on their own for many women within that window. Some women stay on longer because they tolerate it well and the symptoms come back when they try to stop. A small group stays on indefinitely.

When it's time to come off, we don't usually stop cold. We taper the dose down over a few months, and we watch for symptom recurrence. Some women have a rebound of hot flashes after stopping, and a slow taper minimizes that. The taper isn't because HRT is addictive. It's because abrupt withdrawal can leave you feeling miserable and send you straight back to your prescriber asking to restart.

From a heart perspective, the longer you've been on systemic HRT, the more carefully we should be reviewing whether to continue. The decision becomes individualized. A 60-year-old woman with no cardiovascular risk factors, doing well on a low-dose patch, can usually stay on. A 60-year-old woman who's developed hypertension, gained weight, and has a new family history of breast cancer should probably be tapering.

Common Misconceptions I Hear in Clinic

"HRT will give me a heart attack." For a healthy woman in her early fifties starting transdermal estrogen with micronized progesterone, the absolute increase in cardiac event risk over the next several years is small to zero. The headline studies were on older women using oral synthetic combinations. Different drug, different patient, different result.

"Bioidentical hormones from a compounding pharmacy are safer than what my doctor prescribes." The word "bioidentical" gets used as a marketing term. FDA-approved estradiol and FDA-approved micronized progesterone are bioidentical to your own hormones. They are also exactly what most board-certified gynecologists are prescribing. Compounded hormone preparations from non-FDA-regulated pharmacies have wildly variable potency, no quality control, and the same risk profile as any other estrogen plus progestin combination, with worse oversight. There's no safety advantage and there's a real risk of getting an unpredictable dose.

"If HRT is dangerous, my doctor wouldn't have offered it." Your doctor offered it because for most women in your age and risk category it's a reasonable option, and because hot flashes and night sweats are themselves a quality-of-life problem that's been understudied. Your job is to bring your whole picture into the visit so the decision can be tailored.

"I should keep taking HRT to protect my heart and bones." HRT does protect bones. We don't recommend HRT primarily for heart protection. If your goal is cardiovascular risk reduction, we have stronger and safer tools (blood pressure control, statins where indicated, exercise, weight management, smoking cessation). Bone protection is a real reason some women stay on HRT, and that decision belongs in a conversation with both your gynecologist and someone tracking your bone density.

"Vaginal estrogen will mess up my heart." It won't. Different drug, different absorption, different risk profile entirely.

"I had breast cancer, so I can never use any kind of hormone." Systemic HRT is off the table for most women in this situation. Vaginal estrogen, in coordination with your oncology team, is often acceptable for severe genitourinary symptoms.

What to Discuss With Your Gynecologist and Cardiologist

If you're weighing HRT, the conversation should cover several pieces. Your gynecologist will lead the menopausal symptom and uterine considerations. Your cardiologist or primary care doctor will lead the cardiovascular risk assessment.

Bring a clear picture of your symptoms. Hot flashes, night sweats, sleep disruption, mood changes, joint pain, vaginal and urinary symptoms. Quantify how often they're happening and how much they're affecting your life. Vague answers lead to vague prescribing.

Bring your cardiovascular numbers. Recent blood pressure, recent lipid panel, recent fasting glucose or A1c. If you've had a coronary calcium score or a stress test, bring those too. Your prescriber needs the data to do the math.

Bring your family history. First-degree relatives with breast cancer, ovarian cancer, blood clots, early heart disease, or stroke change the conversation.

Ask about the route. For most women with any risk factors, transdermal wins.

If you have a uterus, ask whether micronized progesterone is being used or whether a synthetic progestin is being prescribed, and why.

Ask what the follow-up plan looks like. A reasonable plan involves a check-in at three months, then annually, with attention to blood pressure, weight, breast exam, and any new symptoms.

Ask what would change the plan. Knowing in advance what would prompt stopping (a new clot, a new breast cancer diagnosis, a heart attack, unexplained vaginal bleeding) helps you stay on top of your own care.

How I Think About It in Practice

When a woman comes to me asking about HRT and the heart, I almost never give her a flat yes or a flat no. The honest answer is that the decision lives in the details of her age, her years since menopause, her cardiovascular risk picture, her family history, her symptoms, and her values. My job is to lay that picture out and help her see where she actually sits.

For most healthy women in their early fifties with disruptive symptoms, modern HRT with a transdermal estrogen and micronized progesterone, started for symptom relief and reviewed every year, is a reasonable option. For women in their sixties asking about HRT for heart protection, the answer from a cardiology standpoint is to look elsewhere. For women with active heart disease, prior breast cancer, or prior clots, systemic HRT is usually off the table, and we focus on non-hormonal symptom relief or low-dose vaginal estrogen if the symptoms are localized.

The story your doctor's mother heard about HRT in 2002 isn't the story we tell in 2026. The trial that drove the headlines studied a particular drug combination in a particular age group. The newer evidence, including the Menopause Society's 2022 position statement and the more recent imaging trials, supports a more nuanced and less fearful approach. If you've been holding off on HRT because of something you read twenty years ago, it's worth a fresh conversation.

Frequently Asked Questions

Does HRT cause heart attacks?

In the original large trial, oral estrogen plus a synthetic progestin in women whose average age was 63 did not reduce heart attacks and raised stroke and clot risk. In women starting hormones within ten years of menopause, the heart attack signal disappeared. For a healthy woman in her early fifties on transdermal estrogen with micronized progesterone, the absolute risk increase for heart attack is small to zero. The drug, dose, route, and timing all matter.

Is the patch really safer than the pill?

For clot and stroke risk, yes. The pill goes through your liver before reaching your bloodstream and ramps up clotting proteins. The patch and the gel skip that liver pass and don't have the same clotting effect. Multiple large studies have found rates of deep vein clots and stroke on transdermal estrogen that look very close to women not on hormones. For women with any cardiovascular risk factors at all, transdermal is the preferred form in most clinics today.

If I had a hysterectomy, do I still need progesterone?

No. Progesterone is added to protect the uterine lining from estrogen-driven overgrowth. If you don't have a uterus, you don't need it. Estrogen-only HRT in women who've had hysterectomies has a more favorable risk profile than combined therapy, including in the original trial data.

What's the difference between bioidentical and synthetic hormones?

"Bioidentical" means the molecule is structurally identical to what your body makes. FDA-approved estradiol and FDA-approved micronized progesterone are bioidentical and are what most modern prescribers use. The marketing of "bioidentical hormones" from compounding pharmacies often implies a safety advantage that isn't there. Compounded preparations have variable dosing and no FDA oversight. The safety advantage you're looking for comes from using FDA-approved products.

How long can I stay on HRT?

There's no hard cutoff. The current view is that HRT can continue as long as symptoms are present and you're being followed annually for risk review. Most women stay on for two to seven years. A smaller group stays longer. Each annual visit should weigh whether the symptoms still warrant treatment and whether your risk profile has changed.

Can I take HRT if I have high blood pressure?

Controlled high blood pressure isn't a hard reason to avoid HRT. We use transdermal estrogen preferentially in this group, keep the dose low, and recheck blood pressure soon after starting. Uncontrolled high blood pressure should be addressed first.

What about HRT after a heart attack or a stroke?

Systemic HRT is not started after a heart attack or stroke in most cases, and women already on it when they have one are usually tapered off in coordination with their cardiology and gynecology teams. Vaginal estrogen for genitourinary symptoms is usually still acceptable.

Will HRT prevent dementia?

The evidence on HRT and dementia is mixed. Some early-start data suggest a possible benefit, and the older late-start data showed potential harm. We don't recommend starting HRT for dementia prevention. If symptom relief is the reason you're on it, the cognitive picture is one more thing your prescriber will weigh.

Is vaginal estrogen safe if I have heart disease?

Yes, in most cases. The dose is so low and the systemic absorption so minimal that blood estrogen levels barely change. Vaginal estrogen has not been linked to heart attack, stroke, or clots. For women with a recent breast cancer history, the decision should involve the oncology team. For most women with cardiovascular disease, vaginal estrogen for genitourinary symptoms is acceptable.

What if I don't want to take hormones at all?

Plenty of women choose not to. Non-hormonal options for hot flashes have improved a lot. Certain antidepressants used at low doses, gabapentin, oxybutynin, and a newer class of drugs targeting the brain's temperature-regulation pathway all work for some women. Lifestyle measures (cooler bedroom, layered clothing, weight management, alcohol reduction, exercise) help too. The conversation about non-hormonal options is one your gynecologist or primary care doctor can lead.

References

1. The North American Menopause Society. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society." Menopause 29, no. 7 (2022): 767-794.

2. Rossouw, Jacques E., Ross L. Prentice, JoAnn E. Manson, et al. "Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause." JAMA 297, no. 13 (2007): 1465-1477.

3. Hodis, Howard N., Wendy J. Mack, Victor W. Henderson, et al. "Vascular Effects of Early Versus Late Postmenopausal Treatment with Estradiol." New England Journal of Medicine 374, no. 13 (2016): 1221-1231.

4. Harman, S. Mitchell, Dennis M. Black, Frederick Naftolin, et al. "Arterial Imaging Outcomes and Cardiovascular Risk Factors in Recently Menopausal Women: A Randomized Trial." Annals of Internal Medicine 161, no. 4 (2014): 249-260.

5. Manson, JoAnn E., Aaron K. Aragaki, Jacques E. Rossouw, et al. "Menopausal Hormone Therapy and Long-Term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials." JAMA 318, no. 10 (2017): 927-938.

6. Mosca, Lori, Emelia J. Benjamin, Kathy Berra, et al. "Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women: 2011 Update." Circulation 123, no. 11 (2011): 1243-1262.

7. Arnett, Donna K., Roger S. Blumenthal, Michelle A. Albert, et al. "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease." Journal of the American College of Cardiology 74, no. 10 (2019): e177-e232.

8. US Preventive Services Task Force. "Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement." JAMA 328, no. 17 (2022): 1740-1746.

9. Canonico, Marianne, Geneviève Plu-Bureau, Gordon D.O. Lowe, and Pierre-Yves Scarabin. "Hormone Replacement Therapy and Risk of Venous Thromboembolism in Postmenopausal Women: Systematic Review and Meta-Analysis." BMJ 336, no. 7655 (2008): 1227-1231.

10. Boardman, Henry M.P., Louise Hartley, Anne Eisinga, et al. "Hormone Therapy for Preventing Cardiovascular Disease in Post-Menopausal Women." Cochrane Database of Systematic Reviews, no. 3 (2015): CD002229.

11. Faubion, Stephanie S., Carol L. Kuhle, Lynne T. Shuster, and Walter A. Rocca. "Long-Term Health Consequences of Premature or Early Menopause and Considerations for Management." Climacteric 18, no. 4 (2015): 483-491.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.